The promise of Immatics’ T-cell redirecting cancer immunotherapy technology for solid tumors has been spotlighted in early clinical studies in heavily pre-treated and refractory cancer patients.
Early clinical studies of Immatics N.V.’s engineered T-cells have seen signals of clinical benefits at low doses in heavily pre-treated patients with solid tumors, which the company suggests may be due to the way it identifies and targets its T-cells, plus its manufacturing process which produces younger T-cells.
The reporting of a therapeutic signal in Immatics’ Phase I studies on 17 March was associated with a 21% increase...
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Despite initial promise, a novel autologous cell transplant therapy for severe heart failure has faced multiple challenges in gaining full approval in Japan, potentially providing learnings for other developers of regenerative medicines.
In this week's podcast edition of Five Must-Know Things: global CEO remuneration; another late-stage loss for Merch KgaA; deals shift to smaller M&A, partnering; Bayer’s Parkinson’s bets bear fruit; and India looks to innovate CAR-T models.
The German major is kicking off Phase II trials for a cell therapy and a gene therapy that could be gamechangers for the progressive neurodegenerative disorder that affects more than 10 million people worldwide.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
